Overexpression of Antiapoptotic MCL-1 Predicts Worse Overall Survival of Patients With Non-small Cell Lung Cancer
| Autor: | Takayuki Nakano, Tetsuhiko Go, Dage Liu, Hiroyasu Yokomise, Nariyasu Nakashima |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Lung Neoplasms Myeloid Cell Gene Expression Apoptosis 03 medical and health sciences 0302 clinical medicine immune system diseases Carcinoma Non-Small-Cell Lung hemic and lymphatic diseases Internal medicine Biomarkers Tumor medicine Humans Lung cancer neoplasms Survival rate Aged Proportional Hazards Models business.industry Hazard ratio General Medicine Middle Aged Prognosis medicine.disease medicine.anatomical_structure ROC Curve Terminal deoxynucleotidyl transferase 030220 oncology & carcinogenesis Myeloid Cell Leukemia Sequence 1 Protein Immunohistochemistry Female business |
| Zdroj: | Anticancer Research. 40:1007-1014 |
| ISSN: | 1791-7530 0250-7005 |
| DOI: | 10.21873/anticanres.14035 |
| Popis: | BACKGROUND/AIM Myeloid cell leukemia-1 (MCL-1) is a member of the B-cell lymphoma-2 (Bcl-2) family of proteins, which regulate the intrinsic (mitochondrial) apoptotic cascade. MCL-1 inhibits apoptosis, which may be associated with resistance to cancer therapy. Therefore, in this study, the clinical role of MCL-1 in non-small cell lung cancer (NSCLC) was explored. PATIENTS AND METHODS This retrospective study included 80 patients with stage 1-3A NSCLC, who underwent surgery without preoperative treatment between 2010 and 2011. MCL-1 expression and Ki-67 index were determined via immunohistochemical staining. Apoptotic index (AI) was determined via terminal deoxynucleotidyl transferase dUTP nick end labeling. RESULTS The receiver operating characteristic curve analysis (area under curve=0.6785) revealed that MCL-1 expression in 30.0% of the NSCLC tumor cells was a significant cut-off for predicting prognosis. Tumors were considered MCL-1-positive if staining was observed in >30% of the cells. Thirty-six tumors (45.0%) were MCL-1-positive. However, there were no significant differences between MCL-1 expression and clinical variables. AI was lower in MCL-1-positive (2.2±3.6%) than in MCL-1-negative (5.2±7.9%) tumors, although the difference was not significant (p=0.1080). The Ki-67 index was significantly higher in MCL-1-positive than in MCL-1-negative tumors (18.0% vs. 3.0%; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|